Would you consider using a targeted agent as induction therapy outside of clinical trial for a patient with stage IIIB (N2) who may be a candidate for surgical resection and has a targetable mutation?  

It’s a data free zone. If the patient is borderline resectable, it may be a reasonable option to try induction TKI for 1mo and re-image and see if the patient can convert to resectable. But there is limited data here. Post op, I would not do adjuvant TKI, but rather chemo or chemoXRT.